

Rec'd PCT/PTO 06 FEB 2006

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this paper (along with any paper referred to as being transmitted therewith) is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450., on:

Date: Feb 2, 2006

By: 

Winsome St. Rose

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Gerd Haberhausen, et al.

)

) EXAMINER: Unassigned

SERIAL NO.: 10/534,955

) ART UNIT: Unassigned

FILED: December 2, 2003 (International Filing Date)

) Confirmation No. N/A

FOR: **METHOD FOR THE DETECTION OF
PATHOGENIC GRAM POSITIVE
BACTERIA FROM THE GENERA
STAPHYLOCOCCUS, ENTEROCOCCUS
AND STREPTOCOCCUS**

)

SEQUENCE LISTING AMENDMENT PURSUANT TO 37 CFR § 1.825

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

A Sequence Listing in compliance with 37 CFR § 1.822 and/or § 1.823 was requested with the "Notice to File Missing Parts of Non-Provisional Application" dated December 23, 2005. Accordingly, pursuant to 37 CFR § 1.825(a), Applicants herewith submit three substitute sheets with an amended Sequence Listing. In particular, section <213> for each sequence has been amended to provide that the sequence is Artificial, while corresponding sections <223> clarify that the particular sequence is an oligonucleotide primer or an oligonucleotide probe. In addition, the entry for SEQ ID NO 11 has been deleted, since it is identical to the sequence corresponding to SEQ ID NO 6. Support for these amendments is replete throughout the application as filed. See, e.g., Examples 1 and 2. These substitute sheets include no new matter.

In addition, pursuant to 37 CFR § 1.825(b), Applicants herewith also submit a substitute copy of the computer readable form of the Sequence Listing. This computer readable copy is the same as the substitute copy of the Sequence Listing referred to above.

Applicants respectfully request that all of these amendments be entered.

Respectfully submitted,

Date: February 2, 2006



Christopher C. Sappenfield
Reg. No. 45,073

Roche Molecular Systems, Inc.
1145 Atlantic Avenue
Alameda, CA 94501
Tele:(510) 814-2800
Fax: (510) 814-2973